The compatibility caused by injection of Nicarpine ® 10 mg / 10 mL (Nicarpine ® ) from a side tube into an intravenous line infused with Replas ® 1 Injection (Replas ® 1) and Novo-Heparin ® 10,000 units / 10 mL for Injection (Novo-Heparin ® ) was investigated. We observed a mixed solution of each constituent of Replas ® 1 and Novo-Heparin ® with Nicarpine ® , and measured the IR spectrum of the precipitate and the 1 H-NMR spectrum of a saturated solution of the mixture of heparin and nicardipine. Our findings suggested that the compatibility was caused by an intermolecular interaction between heparin and nicardipine when in a 1:2 ration via the formation of a salt between the sulfate group and/or the carboxylic group of heparin and the amino group of nicardipine.
Introduction
Injectable drugs are prepared on the premise of administration as a single item. However, in therapeutically needed cases, to reduce pain or for ef- 
Compatibility of Heparin Sodium in Intravenous Line with Nicardipine Injected from a Side Tube via T-shape Stopcock
Takafumi Hayashi 1 , Koji Uwai ＊2 , Eri Sasaki medical ward. 1, 2) Thus, for proper use of pharmaceutical preparations, pharmacists, who have knowledge of physics and chemistry, are required to be actively involved with issues related to drug compatibility.
The injection of Nicarpine ® 10 mg / 10 mL (Nicarpine ® ) from a side tube to an intravenous line infused with Replas ® 1 Injection (Replas ® 1)
and Novo-Heparin ® 10,000 units / 10 mL for Injection (Novo-Heparin ® ) is frequently performed.
However, it has recently been found that white turbidity in the intravenous line and syringe is occasionally observed at the bedside. In the Interview Form of Nicarpine ® , the combination of heparin sodium and nicardipine is absolutely incompatible because the prescription is formed shortly after mixing, 3) but in this case, it is formed in a mixture of undiluted solution of Nicarpine ® and heparin sodium (5,000 U / 5 mL). On the other hand, cases have been reported in which heparin sodium is diluted with an infusion solution.
Consequently, it is insufficient to consider this case within the information contained in the Interview Form.
In this study, to provide information to better evaluate whether this intravenous system is suitable for operation from the perspective of a pharmacist, the scientific basis of this compatibility and the structure of the precipitate were chemically investigated.
Materials and Methods
Novo-Heparin ® 
Identification of the constituents causing the compatibility in the infusion solution
1.1 Reproducing the compatibility in the same manner by putting in practice in a medical setting In accordance with common procedures, the infusion system currently in place was replicated ( Fig. 1) . A mixed solution of Replas ® 1 (500 mL) and Novo-Heparin ® (10 mL), as an infusion solution, was passed into an intravenous line by an in- (Table 1) .
Characterization of the precipitates formed by the compatibility

Results
Identification of the constituents causing the compatibility in the infusion solution
Furthermore, by repeating the obstruction, subsequent alarm activation, and successive relief of obstruction, white turbidity was observed in the whole of the inner side of the syringe, and gradually the precipitates were observed. Finally, precipi-tates were also observed in the intravenous line. . 3A) with that of nicardipine ( Fig. 3B ) and
Characterization of the precipitates formed by the compatibility
heparin sodium ( Fig. 3C) , signals in the supernatant derived from nicardipine (the encircled part in Fig. 3A) shifted to a lower eld than those of nicardipine ( Fig. 3B) .
Compatibility between chondroitin sulfate and nicardipine
No change in the appearance of a precipitate was observed after the addition of chondroitin sulfate to nicardipine even if the addition of equivalent moles of heparin sodium of precipitate formation.
Quantitative determination of nicardipine hy-
drochloride content in the precipitate formed by the compatibility 1 H-NMR spectra of the CHCl3-extracted compounds from the alkalified aqueous solution of the precipitate (Fig. 4) were completely consistent with those of nicardipine.
Considering the extraction ratio of the precipitate to the residue of the CHCl3-extracted layer ( 
Discussion
Recently, it was found at the bed side that white turbidity formed in the intravenous line and syringe -a rare observation -in a system in which Nicarpine ® was injected from a side tube by a syringe pump at 8 mL/min to an intravenous line of 500 mL of Replas ® 1 and 10 mL of Novo-Heparin ® owing by an infusion at 20 mL/min. It was inferred that these cases were caused by compatibility. No turbidity was observed in the line and syringe in bedside-replicated situation (Fig. 1) .
However, white turbidity was observed in the upper part of the syringe constructing the line force downstream of the T-shape stopcock ( Table 1) .
Actually, when compatibility was detected as a white precipitate at the bedside, it was reported through the activation of an alarm. Furthermore, by repeating the obstruction, subsequent alarm activation, and successive relief of obstruction, other hand, although there are many reports that variation in pH causes a compatibility involving a change in appearance, 1) in this case compatibility was not derived from a variation in pH ( Table 3) .
Speci cally, pH variation at pH 0.13 in this study resulted in a change in appearance although this pH value was much lower than the pH point of variation (i.e., the pH value at which a change in appearance is observed following the addition of HCl or NaOH solution to a substrate) of nicardipine (http://www3.osaka-ohtani.ac.jp/ph/pre_jitumu/pdf/1-5.pdf). It is suggested that the formation of precipitates in this case was caused by the compatibility between heparin sodium and nicardipine.
Characterizing the precipitate formed by compatibility might provide valuable information not only to determine its cause but also to consider a way to avoid it. Thus, to obtain structural information of the precipitate, IR spectra and 1 H-NMR spectra were measured and their structural features were considered by comparing with spectra of nicardipine hydrochloride and heparin sodium.
Comparing the IR spectrum of the precipitate with those of nicardipine hydrochloride and heparin sodium (Fig. 2) , the absorbance based on the sulfate salt around 1220 and 1440 cm -1 (stretching vibration) in heparin sodium shifted and the absorbance based on the saturated tertiary amine salt around 2200-2700 cm -1 (stretching vibration) 9) in nicardipine hydrochloride disappeared. Furthermore, when comparing the 1 H-NMR spectrum of the precipitate with that of nicardipine hydrochloride and heparin sodium (Fig. 3) , signals Heparin sodium is known to cause compatibility easily and reportedly forms a precipitate by binding to basic drugs in near neutral solution. 10, 11) It is a heterogeneous mixture of acidic mucopolysaccharides and is composed of alternately-α1, If compatibility of the injection should occur, normally an operation is suspended. However, for a pharmacist, it is important to understand how to approach the compatibility so as to execute the operation without changing the purpose of the prescription. As shown in Table 1 , the compati- 
